Patent ID: 9655963
Date: 2017-05-23
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method of treating IgA nephropathy in a subject, the method comprising: a. obtaining a biological sample from a subject; b. determining a level of IgG, IgA1, or both IgG and IgA1 specific for the hinge region of a galactose-deficient IgA1 in the sample; c. determining a level of galactose-deficient IgA1 in the sample, wherein an increase in the level of IgG, IgA1, or both IgG and IgA1 specific for the hinge region of galactose-deficient IgA1 and an increase in the level of galactose-deficient IgA1 in the sample as compared to a control indicates the subject has or is at risk of developing IgA nephropathy, wherein the level of galactose-deficient IgA1 in the subject is detected using an antibody specific for a galactose-deficient hinge-region O-linked glycan of IgA1; and d. treating the IgA nephropathy in the subject.